苏格兰加巴喷丁类药物处方、阿片类与苯二氮䓬类共处方及相关死亡趋势
研究分析苏格兰2006至2016年加巴喷丁类药物处方、社会人口学、共处方及死亡率数据,发现加巴喷丁处方量增加4倍、普瑞巴林增加16倍,60%长期使用者共处方阿片类或苯二氮䓬类,处方者年龄标化死亡率是苏格兰人群的2倍,药物相关死亡中加巴喷丁类和普瑞巴林贡献增加,且部分死者未获处方。
要点
- 长期使用者中60%共处方阿片类或苯二氮䓬类
- 处方者年龄标化死亡率为一般人群2.16倍
核心结论
- 加巴喷丁类药物处方、危险共处方及死亡(含药物相关死亡)自2006年以来大幅增加。
- 老年人、女性及贫困地区居民更可能获得处方。
- 加巴喷丁类药物对药物相关死亡的贡献可能与非法使用及处方药转移更相关。
研究设计与样本
- 分析苏格兰NHS信息服务中心2006-2016年全国处方、社会人口学数据及邓迪大学健康信息中心死亡率数据。
- 从苏格兰国家记录和Tayside药物死亡数据库识别涉及加巴喷丁类药物的药物相关死亡。
主要发现
- 2006至2016年,加巴喷丁处方数从164 630增至694 293(4倍),普瑞巴林从27 094增至435 490(16倍)。
- 2016年 recurrent users(≥3次处方)平均年龄58.1岁,女性占62.5%,更可能居住在贫困地区。
- 60%的 recurrent users 共处方阿片类、苯二氮䓬类或两者(阿片类49.9%,苯二氮䓬类26.8%,两者17.1%)。
- 处方加巴喷丁类药物者年龄标化死亡率是苏格兰人群的2倍(相对风险2.16,95%CI 2.08-2.25)。
- 药物相关死亡中加巴喷丁贡献地区23% vs 全国15%,普瑞巴林21% vs 7%;Tayside地区22例(39%)药物相关死亡涉及加巴喷丁类,其中17例(77%)未获处方。
临床怎么用
- 临床处方加巴喷丁类药物时应评估共处方阿片类或苯二氮䓬类的风险。
- 关注老年、女性及贫困地区患者的用药安全与滥用风险。
- 警惕处方药转移及非法使用对药物相关死亡的贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gabapentinoid drugs (gabapentin and pregabalin) are effective in neuropathic pain, which has a prevalence of ∼7%. Concerns about increased prescribing have implications for patient safety, misuse, and diversion. Drug-related deaths (DRDs) have increased and toxicology often implicates gabapentinoids. We studied national and regional prescribing rates (2006-2016) and identified associated sociodemographic factors, co-prescriptions and mortality, including DRDs. METHODS: National data from the Information Service Division, NHS Scotland were analysed for prescribing, sociodemographic, and mortality data from the Health Informatics Centre, University of Dundee. DRDs in which gabapentinoids were implicated were identified from National Records of Scotland and Tayside Drug Death Databases. RESULTS: From 2006 to 2016, the number of gabapentin prescriptions in Scotland increased 4-fold (164 630 to 694 293), and pregabalin 16-fold (27 094 to 435 490). In 2016 'recurrent users' (three or more prescriptions) had mean age 58.1 yr, were mostly females (62.5%), and were more likely to live in deprived areas. Of these, 60% were co-prescribed an opioid, benzodiazepine, or both (opioid 49.9%, benzodiazepine 26.8%, both 17.1%). The age-standardised death rate in those prescribed gabapentinoids was double that in the Scottish population (relative risk 2.16, 95% confidence interval 2.08-2.25). Increases in gabapentinoids contributing to cause of DRDs were reported regionally and nationally (gabapentin 23% vs 15%; pregabalin 21% vs 7%). In Tayside, gabapentinoids were implicated in 22 (39%) of DRDs, 17 (77%) of whom had not received a prescription. CONCLUSIONS: Gabapentinoid prescribing has increased dramatically since 2006, as have dangerous co-prescribing and death (including DRDs). Older people, women, and those living in deprived areas were particularly likely to receive prescriptions. Their contribution to DRDs may be more related to illegal use with diversion of prescribed medication.
引用
- Torrance N, Veluchamy A, Zhou Y, et al. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. Br J Anaesth. 2020. PMID: 32571568. doi:10.1016/j.bja.2020.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。